What question did this study set out to answer?

To evaluate the prognostic capacity of admission von Willebrand factor antigen levels in predicting major adverse cardiovascular events and mortality in acute coronary syndrome patients.

September 3, 2026Annals of African Medicine

Elevated admission VWF linked to ~282% higher 3-month MACE risk in ACS patients.

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Acute Coronary Syndrome (n=121). Intervention: Elevated VWF antigen levels (>26.75) vs. Lower VWF antigen levels. Primary outcome: Major adverse cardiovascular events (MACE) at 3 months (HR 3.82, 95% CI 1.89-7.72, p=<0.001).

Q: What does this research mean for the field?

Elevated admission von Willebrand factor (VWF) antigen levels independently predict an increased risk of major adverse cardiovascular events at 3 months in patients with acute coronary syndrome. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Why the study?

ACS remains a major global cause of morbidity and mortality, requiring early identification of high-risk patients to guide treatment.

Do elevated von Willebrand factor (VWF) antigen levels predict major adverse cardiovascular events in patients with acute coronary syndrome?

Population

121 ACS patients at a tertiary care hospital

Comparison

Elevated vs lower von Willebrand factor antigen levels

Design

Prospective observational study

Follow-up

3 months

Key result

Elevated admission VWF antigen levels (>26.75) were an independent predictor of major adverse cardiovascular events at 3 months in patients with acute coronary syndrome (HR 3.82; 95% CI 1.89-7.72; P<0.001).

Authors

PRPreethi Yazhini Ravichandran KMKrishnaswamy Madhavan

Discussion

Member takes

Overview

May support short-term risk stratification in ACS; hypothesis-generating and requires prospective validation before clinical adoption.

Key Points

To evaluate the prognostic capacity of admission von Willebrand factor antigen levels in predicting major adverse cardiovascular events and mortality in acute coronary syndrome patients.
Prospective observational study conducted at a tertiary care hospital enrolling 121 patients with acute coronary syndrome.
VWF antigen levels were measured at admission using enzyme-linked immunosorbent assay (ELISA).
Patients were prospectively followed up at 4 weeks and 3 months for composite MACE (heart failure, angina, myocardial infarction, stroke, acute decompensated heart failure, and death) and all-cause mortality.
At 3 months, MACE occurred in 34.8% of patients, with median VWF antigen levels significantly higher in those with MACE compared to those without (31.90 [IQR: 27.70–33.50] vs. 12.30 [IQR: 6.00–30.20], P < 0.0001).
Multivariate Cox regression identified VWF antigen >26.75 as an independent predictor of 3-month MACE (adjusted HR: 3.82, 95% CI: 1.89–7.72, P < 0.001; AUC: 0.788, sensitivity: 85.0%, specificity: 69.33%).
Mortality reached 2.5% at 1 month and 3.5% at 3 months, but differences in VWF antigen levels between survivors and deceased patients were not statistically significant (P = 0.243).

Study Design

Type

Observational (n=121)

Multicenter

Structured PICO

Do elevated von Willebrand factor (VWF) antigen levels predict major adverse cardiovascular events in patients with acute coronary syndrome?

Population

121 patients with acute coronary syndrome, followed for 3 months to evaluate VWF antigen as a prognostic marker.

Exposure

Elevated von Willebrand factor (VWF) antigen levels (>26.75)

Comparator

Lower von Willebrand factor (VWF) antigen levels (≤26.75)

Outcome

Major adverse cardiovascular events (MACE), defined as a composite of heart failure, angina, myocardial infarction, stroke, acute decompensated heart failure, and death at 4 weeks and 3 monthscomposite

Main Result

Hazard Ratio: 3.82 (95% CI 1.89–7.72)

p-value: p=<0.001

Elevated admission VWF antigen levels (>26.75) independently predict a nearly four-fold increased risk of MACE at 3 months in patients with acute coronary syndrome.

Cite This Study

Ravichandran et al. (2026) conducted an observational in Acute Coronary Syndrome (n=121). Elevated VWF antigen levels (>26.75) vs. Lower VWF antigen levels was evaluated on Major adverse cardiovascular events (MACE) at 3 months (HR 3.82, 95% CI 1.89-7.72, p=<0.001). Elevated admission VWF antigen levels (>26.75) were an independent predictor of major adverse cardiovascular events at 3 months in patients with acute coronary syndrome (HR 3.82; 95% CI 1.89-7.72; P<0.001).

synapsesocial.com/papers/6a993626636c6408cfa7ef28 https://doi.org/10.4103/aam.aam_489_26

View Full Paper

Ask AI

Bookmark

September 3, 2026Annals of African Medicine

Elevated admission VWF linked to ~282% higher 3-month MACE risk in ACS patients.

View Full Paper

Ask AI

Bookmark

Why the study?

ACS remains a major global cause of morbidity and mortality, requiring early identification of high-risk patients to guide treatment.

Do elevated von Willebrand factor (VWF) antigen levels predict major adverse cardiovascular events in patients with acute coronary syndrome?

Population

121 ACS patients at a tertiary care hospital

Comparison

Elevated vs lower von Willebrand factor antigen levels

Design

Prospective observational study

Follow-up

3 months

Key result

Authors

PRPreethi Yazhini Ravichandran KMKrishnaswamy Madhavan

Discussion

Member takes

Overview

May support short-term risk stratification in ACS; hypothesis-generating and requires prospective validation before clinical adoption.

Key Points

To evaluate the prognostic capacity of admission von Willebrand factor antigen levels in predicting major adverse cardiovascular events and mortality in acute coronary syndrome patients.
Prospective observational study conducted at a tertiary care hospital enrolling 121 patients with acute coronary syndrome.
VWF antigen levels were measured at admission using enzyme-linked immunosorbent assay (ELISA).
Patients were prospectively followed up at 4 weeks and 3 months for composite MACE (heart failure, angina, myocardial infarction, stroke, acute decompensated heart failure, and death) and all-cause mortality.
At 3 months, MACE occurred in 34.8% of patients, with median VWF antigen levels significantly higher in those with MACE compared to those without (31.90 [IQR: 27.70–33.50] vs. 12.30 [IQR: 6.00–30.20], P < 0.0001).
Multivariate Cox regression identified VWF antigen >26.75 as an independent predictor of 3-month MACE (adjusted HR: 3.82, 95% CI: 1.89–7.72, P < 0.001; AUC: 0.788, sensitivity: 85.0%, specificity: 69.33%).
Mortality reached 2.5% at 1 month and 3.5% at 3 months, but differences in VWF antigen levels between survivors and deceased patients were not statistically significant (P = 0.243).

Study Design

Type

Observational (n=121)

Multicenter

Structured PICO

Do elevated von Willebrand factor (VWF) antigen levels predict major adverse cardiovascular events in patients with acute coronary syndrome?

Population

121 patients with acute coronary syndrome, followed for 3 months to evaluate VWF antigen as a prognostic marker.

Exposure

Elevated von Willebrand factor (VWF) antigen levels (>26.75)

Comparator

Lower von Willebrand factor (VWF) antigen levels (≤26.75)

Outcome

Main Result

Hazard Ratio: 3.82 (95% CI 1.89–7.72)

p-value: p=<0.001

Elevated admission VWF antigen levels (>26.75) independently predict a nearly four-fold increased risk of MACE at 3 months in patients with acute coronary syndrome.

Cite This Study

synapsesocial.com/papers/6a993626636c6408cfa7ef28 https://doi.org/10.4103/aam.aam_489_26

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark